Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
Mereo BioPharma Group’s Phase 2b dose-ranging “Asteroid” clinical study of setrusumab (BPS-804), an anti-sclerostin antibody, in adults with Type I,
AstraZeneca and FibroGen’s pooled cardiovascular (CV) safety analyses showed that roxadustat, an oral first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), did not increase the risk of MACE, MACE+ and all-cause mortality in non dialysis-dependent (NDD) patients compared to placebo and dialysis-dependent (DD) patients compared to epoetin alfa, a current medicine used to treat anaemia.
Vaccibody with first neoantigen cancer vaccine to show induction of strong cancer-specific immune responses
Vaccibody AS, a clinical-stage biopharmaceutical company focused on cancer vaccines, announced in a press release on November 5, 2019 the positive initial data from the ongoing VB N-01 (DIRECT-01) phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine.
Scynexis biotechnology company on Thursday announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).
HLS Therapeutics posted $1.9 million net loss in the third quarter 2019, compared to the same period last year, when it was compared to net loss of $19.7 million, boosted by Canadian-based clozaril sales in the last day of Q2.
Entrome SA, a clinical-stage biopharmaceutical company will work with Memorial Sloan Kettering Cancer Center (MSK) in New York City to evaluate the potential of gut microbiome-derived antigens for development as cancer immunotherapies.
Arix Bioscience said Wednesday that its portfolio company Artios Pharma Ltd, has entered in-licensing agreement of a small-molecule ATR inhibitor programme from The University of Texas MD Anderson Cancer Center and ShangPharma.
Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.